2013
DOI: 10.1039/c2cy20350b
|View full text |Cite
|
Sign up to set email alerts
|

The use of enzymes in organic synthesis and the life sciences: perspectives from the Swiss Industrial Biocatalysis Consortium (SIBC)

Abstract: The potential of biotechnology by means of biocatalysis or biosynthesis in organic synthesis is far from being fully exploited. For this reason a group of life science companies active in pharmaceuticals, flavour and fragrance, vitamin and fine chemicals businesses describe some examples of the use of enzymes in industrial organic synthesis and discuss why enzymes are still the exception rather than the rule in organic synthesis.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
56
0

Year Published

2014
2014
2018
2018

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 100 publications
(63 citation statements)
references
References 33 publications
0
56
0
Order By: Relevance
“…In the conventional activation conditions, with succinic anhydride, the lipase PCL provides the best conversions (13 % \ C \ 80 %) and selectivities (1 \ E \ 46) for the studied substrates [1][2][3][4][5][6][7]. The best selectivity was observed for a-tetralol 1, E = 25 and C = 34 % (entry 2).…”
Section: Resultsmentioning
confidence: 80%
See 1 more Smart Citation
“…In the conventional activation conditions, with succinic anhydride, the lipase PCL provides the best conversions (13 % \ C \ 80 %) and selectivities (1 \ E \ 46) for the studied substrates [1][2][3][4][5][6][7]. The best selectivity was observed for a-tetralol 1, E = 25 and C = 34 % (entry 2).…”
Section: Resultsmentioning
confidence: 80%
“…In recent years, biocatalyzed kinetic resolution associated with chemo-enzymatic methodologies are tools frequently used to prepare enantiomerically active molecules; its potential in organic catalysis is far from being fully exploited [1][2][3][4]. Very high enantio-, regio-and chemo-selectivities can be achieved using hydrolases due to the strict recognition of the substrate by the enzyme [5][6][7].…”
Section: Introductionmentioning
confidence: 99%
“…Diverse examples of chiral medicaments are produced by biocatalyzed process, which include atorvastatin (Lipitor), rosuvastatin (Crestor), sitagliptin (Januvia), and montelukast (Singulair). Industrial biocatalysis are still an exception and not a rule, although the use of enzymes has been gaining increasing attention for the organic synthesis of high added-value products, such as pharmaceuticals, flavors and fragrances, vitamins, and fine chemicals as well as for some commodities [156,227]. Companies such as Avecia, Basf, Evonik, DSM, Dow Pharma, and Lonza use enzymes or cells for chiral synthesis of their products [228].…”
Section: Pharmaceutical Products and Chemicalsmentioning
confidence: 99%
“…The lack of enzyme stability of mesophilic enzymes renders them inefficient for the harsh reaction conditions required in industrial processes. For this reason, the use of biocatalysts in organic reactions represents only a small fraction of the potential industrial market (Meyer et al, 2012). Thermotolerant bacteria have attracted industrial and biotechnological attention as their enzymes are well suited for harsh industrial processes (Abdel-Rahman et al, 2016;Archna et al, 2015;Verma et al, 2015).…”
Section: Introductionmentioning
confidence: 99%